Literature DB >> 21627987

Reactive oxygen species in cardiovascular disease.

Koichi Sugamura1, John F Keaney.   

Abstract

Based on the "free radical theory" of disease, researchers have been trying to elucidate the role of oxidative stress from free radicals in cardiovascular disease. Considerable data indicate that reactive oxygen species and oxidative stress are important features of cardiovascular diseases including atherosclerosis, hypertension, and congestive heart failure. However, blanket strategies with antioxidants to ameliorate cardiovascular disease have not generally yielded favorable results. However, our understanding of reactive oxygen species has evolved to the point at which we now realize these species have important roles in physiology as well as pathophysiology. Thus, it is overly simplistic to assume a general antioxidant strategy will yield specific effects on cardiovascular disease. Indeed, there are several sources of reactive oxygen species that are known to be active in the cardiovascular system. This review addresses our understanding of reactive oxygen species sources in cardiovascular disease and both animal and human data defining how reactive oxygen species contribute to physiology and pathology.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21627987      PMCID: PMC3156326          DOI: 10.1016/j.freeradbiomed.2011.05.004

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  297 in total

Review 1.  Myocardial protection at a crossroads: the need for translation into clinical therapy.

Authors:  Roberto Bolli; Lance Becker; Garrett Gross; Robert Mentzer; David Balshaw; David A Lathrop
Journal:  Circ Res       Date:  2004-07-23       Impact factor: 17.367

2.  Effects of edaravone on reperfusion injury in patients with acute myocardial infarction.

Authors:  Kenichi Tsujita; Hideki Shimomura; Hiroaki Kawano; Jun Hokamaki; Masaya Fukuda; Takuro Yamashita; Satoru Hida; Yoshinori Nakamura; Yasuhiro Nagayoshi; Tomohiro Sakamoto; Michihiro Yoshimura; Hidekazu Arai; Hisao Ogawa
Journal:  Am J Cardiol       Date:  2004-08-15       Impact factor: 2.778

3.  Serum myeloperoxidase levels independently predict endothelial dysfunction in humans.

Authors:  Joseph A Vita; Marie-Luise Brennan; Noyan Gokce; Shirley A Mann; Marlene Goormastic; Mehdi H Shishehbor; Marc S Penn; John F Keaney; Stanley L Hazen
Journal:  Circulation       Date:  2004-08-23       Impact factor: 29.690

4.  Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease.

Authors:  Lemin Zheng; Benedicta Nukuna; Marie-Luise Brennan; Mingjiang Sun; Marlene Goormastic; Megan Settle; Dave Schmitt; Xiaoming Fu; Leonor Thomson; Paul L Fox; Harry Ischiropoulos; Jonathan D Smith; Michael Kinter; Stanley L Hazen
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

5.  Urinary biopyrrins levels are elevated in relation to severity of heart failure.

Authors:  Jun Hokamaki; Hiroaki Kawano; Michihiro Yoshimura; Hirofumi Soejima; Shinzo Miyamoto; Ichiro Kajiwara; Sunao Kojima; Tomohiro Sakamoto; Seigo Sugiyama; Nobutaka Hirai; Hideki Shimomura; Yasuhiro Nagayoshi; Kenichi Tsujita; Izuru Shioji; Shinya Sasaki; Hisao Ogawa
Journal:  J Am Coll Cardiol       Date:  2004-05-19       Impact factor: 24.094

Review 6.  Lipoxygenase pathways in atherogenesis.

Authors:  Lei Zhao; Colin D Funk
Journal:  Trends Cardiovasc Med       Date:  2004-07       Impact factor: 6.677

7.  Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity.

Authors:  M Cristina Polidori; Domenico Praticó; Ketty Savino; Joshua Rokach; Wilhelm Stahl; Patrizia Mecocci
Journal:  J Card Fail       Date:  2004-08       Impact factor: 5.712

8.  Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction.

Authors:  Stefan Janssens; Peter Pokreisz; Luc Schoonjans; Marijke Pellens; Pieter Vermeersch; Marc Tjwa; Peter Jans; Marielle Scherrer-Crosbie; Michael H Picard; Zsolt Szelid; Hilde Gillijns; Frans Van de Werf; Desire Collen; Kenneth D Bloch
Journal:  Circ Res       Date:  2004-03-25       Impact factor: 17.367

Review 9.  F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases.

Authors:  Domenico Praticò; Joshua Rokach; John Lawson; Garret A FitzGerald
Journal:  Chem Phys Lipids       Date:  2004-03       Impact factor: 3.329

10.  Pressure overload-induced myocardial hypertrophy in mice does not require gp91phox.

Authors:  Melanie Maytin; Deborah A Siwik; Masahiro Ito; Lei Xiao; Douglas B Sawyer; Ronglih Liao; Wilson S Colucci
Journal:  Circulation       Date:  2004-02-23       Impact factor: 29.690

View more
  221 in total

1.  Mitochondrial flash as a novel biomarker of mitochondrial respiration in the heart.

Authors:  Guohua Gong; Xiaoyun Liu; Huiliang Zhang; Shey-Shing Sheu; Wang Wang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-08-14       Impact factor: 4.733

Review 2.  Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release.

Authors:  Nazila Kamaly; Basit Yameen; Jun Wu; Omid C Farokhzad
Journal:  Chem Rev       Date:  2016-02-08       Impact factor: 60.622

Review 3.  Mitochondria as a source and target of lipid peroxidation products in healthy and diseased heart.

Authors:  Ethan J Anderson; Lalage A Katunga; Monte S Willis
Journal:  Clin Exp Pharmacol Physiol       Date:  2012-02       Impact factor: 2.557

4.  Variation in Free Radical Yields from U.S. Marketed Cigarettes.

Authors:  Reema Goel; Zachary Bitzer; Samantha M Reilly; Neil Trushin; Jonathan Foulds; Joshua Muscat; Jason Liao; Ryan J Elias; John P Richie
Journal:  Chem Res Toxicol       Date:  2017-03-20       Impact factor: 3.739

Review 5.  The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases.

Authors:  Prashant Deshmukh; Sruthi Unni; Gopinatha Krishnappa; Balasundaram Padmanabhan
Journal:  Biophys Rev       Date:  2016-12-06

Review 6.  Nanoplatforms for Targeted Stimuli-Responsive Drug Delivery: A Review of Platform Materials and Stimuli-Responsive Release and Targeting Mechanisms.

Authors:  Yuzhe Sun; Edward Davis
Journal:  Nanomaterials (Basel)       Date:  2021-03-16       Impact factor: 5.076

7.  Increased Mutagen Sensitivity and DNA Damage in Pulmonary Arterial Hypertension.

Authors:  Chiara Federici; Kylie M Drake; Christina M Rigelsky; Lauren N McNelly; Sirena L Meade; Suzy A A Comhair; Serpil C Erzurum; Micheala A Aldred
Journal:  Am J Respir Crit Care Med       Date:  2015-07-15       Impact factor: 21.405

Review 8.  The effects of hypertension on the cerebral circulation.

Authors:  Paulo W Pires; Carla M Dams Ramos; Nusrat Matin; Anne M Dorrance
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-12       Impact factor: 4.733

9.  Superoxide dismutase mimetic, MnTE-2-PyP, attenuates chronic hypoxia-induced pulmonary hypertension, pulmonary vascular remodeling, and activation of the NALP3 inflammasome.

Authors:  Leah R Villegas; Dylan Kluck; Carlie Field; Rebecca E Oberley-Deegan; Crystal Woods; Michael E Yeager; Karim C El Kasmi; Rashmin C Savani; Russell P Bowler; Eva Nozik-Grayck
Journal:  Antioxid Redox Signal       Date:  2013-02-05       Impact factor: 8.401

10.  Paraquat exposure and Sod2 knockdown have dissimilar impacts on the Drosophila melanogaster carbonylated protein proteome.

Authors:  Suresh K Narayanasamy; David C Simpson; Ian Martin; Mike Grotewiel; Scott Gronert
Journal:  Proteomics       Date:  2014-09-19       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.